Mental health treatment
The clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, atai Life Sciences, has launched a platform company committed to developing new chemical entities (NCEs). Invyxis, the new, wholly owned platform company, aims to bring proven medicinal chemistry tools and comprehensive biological screening approaches to atai’s growing enterprise of drug discovery and design.
